TrialSignal
Clinical trial intelligence report
Investigation of Antidepressant Efficacy of Oral Ketamine Treatment
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT02992496
Status
UNKNOWN
Phase
PHASE2
Sponsor
Medical University of Vienna
Executive brief
Investment-Ready Snapshot
Investigation of Antidepressant Efficacy of Oral Ketamine Treatment is a PHASE2 clinical asset sponsored by Medical University of Vienna in Major Depressive Episode. SEO and diligence focus: Ketamine, Midazolam Hydrochloride, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02992496
Indication
Major Depressive Episode
Modality
small molecule
Target
Ketamine, Midazolam Hydrochloride
Intervention
Ketamine, Midazolam Hydrochloride
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.